• December 9, 2019

Aleta Biotherapeutics Announces Oral Presentation at the 61st American Society of Hematology Annual Meeting (ASH) - Odessa American: Business

e-Edition Subscribe

Aleta Biotherapeutics Announces Oral Presentation at the 61st American Society of Hematology Annual Meeting (ASH)

Print
Font Size:
Default font size
Larger font size

Posted: Monday, December 2, 2019 6:01 am | Updated: 6:31 am, Mon Dec 2, 2019.

NATICK, Mass.--(BUSINESS WIRE)--Dec 2, 2019--

Aleta Biotherapeutics, a privately held immuno-oncology company focused on transforming cellular therapeutics to allow a broad spectrum of cancer indications to be targeted, today announced that Paul Rennert, Ph.D., President and Chief Scientific Officer, will deliver an oral presentation at the 61 st ASH Annual Meeting & Exposition, December 7 – 10, 2019, Orange County Convention Center, Orlando, FL.

“The 61 st ASH Annual Meeting will be an important opportunity to present mechanistic studies and extensive in vitro and in vivo results from our novel CD19-anti-CD20 bridging protein technology,” said Paul Rennert, Ph.D., President and Chief Scientific Officer of Aleta Biotherapeutics. “We look forward to advancing the development of this novel therapy based on the data we will be presenting on December 7.”

Oral Presentation Details

Title:252 A Novel CD19-Anti-CD20 Bridging Protein Prevents and Reverses CD19-Negative Relapse from CAR19 T Cell Treatment in vivo

Session Name: 703. Adoptive Immunotherapy: Mechanisms and New Approaches: Mechanisms

Presenter: Paul Rennert, Ph.D.

Session Date: Saturday, December 7, 2019

Session Time: 2:00 PM - 3:30 PM

Presentation Time: 3:15 PM

Location: Orange County Convention Center, Valencia A (W415A)

About Aleta Biotherapeutics

Aleta Biotherapeutics is an immuno-oncology company focused on transforming cellular therapeutics to allow a broad spectrum of cancer indications to be targeted, including currently intractable solid tumors. The company was founded by Paul Rennert and Roy Lobb, who bring extensive scientific and leadership experience in immunology, oncology and drug development to this new enterprise. Aleta has created a unique portfolio of multi-antigen targeting solutions for cell therapy, designed to address the critical issues of CAR-T persistence, tumor antigen loss leading to patient relapse, and tumor antigen heterogeneity. For more information, visit www.aletabio.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191202005056/en/

CONTACT: Rob Kloppenburg

MacDougall

(617) 930-5595

rkloppenburg@macbiocom.com

KEYWORD: FLORIDA MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: ONCOLOGY HEALTH OTHER HEALTH GENERAL HEALTH PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Aleta Biotherapeutics

Copyright Business Wire 2019.

PUB: 12/02/2019 07:00 AM/DISC: 12/02/2019 07:01 AM

http://www.businesswire.com/news/home/20191202005056/en

© 2019 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Odessa, TX

Current Conditions

Rain Shower
49°
Humidity: 94%
Winds: SE at 8mph
Feels Like: 45°

Your Extended Forecast

Tomorrow

weather
High 60°/Low 34°
Cloudy, periods of rain. Lows overnight in the mid 30s.

tuesday

weather
High 46°/Low 34°
Morning clouds followed by afternoon sun. Highs in the mid 40s and lows in the mid 30s.

wednesday

weather
High 55°/Low 36°
Times of sun and clouds. Highs in the mid 50s and lows in the mid 30s.
Online Features

Pet Central

pets

Having a pet is a lot of responsibility, and we’ll help by giving you lots of tips and tricks! More >>

Fitness

Fitness

Our fitness articles will help teach you how to work out with gym- and home-based exercises. More >>

Crosswords

Crosswords

Enjoy the crosswords challenge in our free daily puzzles, from the harder Sunday crossword to the quicker daily. More >>

Sudoku

Sudoku

Every Sudoku has a unique solution that can be reached logically. Enter numbers into the blank spaces so that each row, column and 3x3 box contains the numbers 1 to 9. More >>




  • ALL-ACCESS: Subscribe to our e-edition and premium website at myoaoa.com.
    You can read your daily newspaper without taking a walk to the driveway.
    Look back at yesterday's newspaper, or issues from months ago with our archive feature.
    Call circulation at 432-337-7314 to sign up today.